Product Pipeline

CPH-101/102 (Anti-PARP)

PARP is a nuclear protein that has been shown to play a role as a master-regulator of major nuclear functions. PARP has been implicated in conditions such as regional heart and muscle ischemia, diabetes, and arthritis amongst others by mediating cell death. PARP is activated by DNA damage and uses NAD as a substrate to synthesize PAR resulting in a significant decrease in available NAD. Inhibition of PARP has been shown to stabilize levels of NAD and ATP (the synthesis of which also requires NAD) and thus preserve ischemic tissues.

CPH-102 inhibits the poly ADP-ribose synthesizing ability of PARP I, both in vitro and in vivo. It acts with remarkable specificity on a number of human cancers in cell culture tests by first inhibiting the malignant phenotype, i.e., the ability to form tumors and metastasize (the spread of cancer). CHP-101 is active both in cell cultures and in vivo as an anti-cancer agent and anti-HIV agent. CHP-101 acts synergistically with CHP-102; therefore the combination of the two drug candidates may prove to be highly effective.

Crimson's expertise lies in its ability to accelerate the life cycle of a drug candidate from labs to market through an integrated approach. Upon in-licensing a candidate from a partner, Crimson will continue to add value at various stages: formulation, optimization and production scale-up of the compound, management of pre-clinical and clinical studies, compilation and submission of registration files to obtain marketing authorization from the Chinese State Food and Drug Administration (SFDA), and subsequently, identification of commercialization strategies and partners .

CPH 103/104 (DIME/DIPE)

CPH-103 and CHP-104 are thyroid hormone analogs without thyroid hormone activity. They are di-iodothyronine derivatives and have been shown to be powerful anti-cancer agents by inhibiting the polymerization of cellular microtubules required for successful cell division. The anti-microtubule activity of these compounds mimics that of Taxol, but without Taxol's toxicity. Crimson has recently received a Chinese patent on the use of thyroxine analogs to treat malignant tumors.